Field Trip Health Ltd

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Field Trip Health & Wellness Ltd

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative Health Schedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or “Reunion”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “REUN” at the opening of the market on August 17, 2022.

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

Field Trip Health Ltd. (NASDAQ:FTRP ) Q1 2023 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Kathleen Heaney - KCSA Strategic Communications Ronan Levy - Chairman and Chief Executive Officer of Field Trip Health & Wellness Joseph Del Moral - Chairman and Chief Executive Officer Donna Wong - Chief Financial Officer Nathan Bryson - Chief Scientific Officer Conference Call Participants Andrew Partheniou - Stifel Nicolaus Patrick Trucchio - H.C.

Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q1 2023 Results - Earnings Call Transcript

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly “Field Trip Health Ltd.”, or the “Company”) (TSX: FTRP, Nasdaq: FTRP), a leader in novel psychedelic drug development, reported fiscal first quarter 2023 results for the three-month period ended June 30, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (the "Company") is pleased to announce that it has filed a listing application in connection with the previously announced intention to list its common shares (the "Shares") on the TSX Venture Exchange (“TSXV”). It is anticipated that the Shares will commence trading on the TSXV under the ticker symbol “FTHW” at the opening of the market on August 17, 2021.

Field Trip Health & Wellness Ltd. Provides Update on TSX Venture Exchange Listing

- Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN" - Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol “FTHW” - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

Field Trip Health Ltd. (FTRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. – Field Trip Discovery to be renamed Reunion Neuroscience Inc., remaining listed on the NASDAQ Stock Market and Toronto Stock Exchange.

Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd.

- First Dosings completed in Australia - Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences - Announces 5:1 Share Consolidation Ratio

Field Trip Announces First Dosings in Phase I Clinical Study of FT-104

Field Trip Health Ltd. (NASDAQ:FTRP ) Q4 2022 Earnings Conference Call June 30, 2022 8:30 AM ET Company Participants Kathleen Heaney - Investor Relations Joseph Del Moral - Co-Founder and Chief Executive Officer Ronan Levy - Co-Founder and Executive Chairman Donna Wong - Chief Financial Officer Paula Hewitt - Vice President and General Counsel Nathan Bryson – Chief Scientific Officer Conference Call Participants Andrew Partheniou - Stifel Patrick Trucchio - H.C.

Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q4 2022 Results - Earnings Call Transcript

TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and provided a business update. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange. - Closing of the arrangement expected to occur in August. - Also announces closing of subscription receipt offering.

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

Constellation Brands

Walgreens

The three major U.S. equity indexes closed lower Monday, with the Nasdaq dipping by 0.72%, the S&P 500 sliding 0.3% and the Dow Jones industrials closing down 0.2%.

Earnings Previews: Constellation Brands, Field Trip Health, NovaGold, Walgreens

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside chat at the H.C. Wainwright 1st Annual Mental Healthcare Conference taking place June 27, 2022.

Field Trip Health Ltd. to Present at the H.C.

- Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice - Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET

TORONTO, June 14, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company" or "Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of its clinics business to Field Trip Health & Wellness Ltd. (“SpinCo”) by way of a plan of arrangement (the "Arrangement"). In order to provide shareholders adequate time to consider the new information as a result of this change, the Company has postponed its special meeting (the "Meeting"), which was previously scheduled for 10:00 a.m. (Toronto Time) on Monday, June 20, 2022, to 10:00 a.m. (Toronto Time) Monday, June 27, 2022. The new information has been placed before Shareholders by management of the Company in a supplement, attached hereto (the "Supplement"), to the management information circular of the Company dated May 20, 2022 (the "Circular") and filed on SEDAR on May 24, 2022.

Field Trip Health Ltd. Announces Increased Participation in Arrangement Financing and Postponement of Shareholder Meeting Date

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic-assisted psychotherapy with 12 locations across North America and Europe, and Nue Life Health (‘Nue Life'), a leader in mental wellness telehealth and at-home ketamine treatments, announced today the launch of Field Trip at Home™ Powered by Nue Life, which provides ketamine treatments from the comfort of a person's home. Through this arrangement, Field Trip now offers increased accessibility and convenience for those interested in pursuing the powerful treatment outcomes of ketamine therapy outside of a clinic setting through Nue Life's at-home and telehealth offerings.

Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home

TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's management team will participate in two investor conferences in May 2022.

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022

TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisions into two independent public companies (the "Transaction"). Field Trip Discovery will be renamed Reunion Neuroscience Inc. (“Reunion”) and Field Trip Health will be renamed Field Trip Health and Wellness Ltd. (“Field Trip H&W”). Concurrent with closing of the Transaction, Field Trip H&W is expected to complete financings for gross proceeds of approximately C$20 million led by Oasis Management Company and the Company (the “Financings”).

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's management team will participate in the following investor conferences in April 2022.

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences

The Allowed Claims include Composition of FT-104 and Provides Protection until 2040 The Allowed Claims include Composition of FT-104 and Provides Protection until 2040

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

Cybin

Mind Medicine MindMed

Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. The post 3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill appeared first on InvestorPlace.

3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill

TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at the Maxim Group 2nd Annual Virtual Growth Conference, hosted by M-Vest, taking place March 28-30, 2022.

Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference

TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will be presenting at the 34th Annual Roth Conference taking place on March 13-15, 2022 in California.

News for Field Trip Health Ltd Stock (FTRP)